Biotech Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Private, Subsidiary
- Established
- 2000-08-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biotechplc.com
Clinical Trials
27
Active:1
Completed:7
Trial Phases
5 Phases
Phase 1:9
Phase 2:6
Phase 3:8
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (34.6%)Phase 3
8 (30.8%)Phase 2
6 (23.1%)Phase 4
2 (7.7%)Not Applicable
1 (3.8%)A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
Phase 4
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: cis-platinumRadiation: IMRT combine with cisplatin concurrent chemotherapyDrug: painkiller
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 171
- Registration Number
- NCT06879691
- Locations
- 🇨🇳
Baotou Cancer Hospital, Baotou, Inner Mongolia, China
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
Phase 3
Completed
- Conditions
- Cervical Squamous Cell CarcinomaPersistent
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06781073
- Locations
- 🇨🇳
Cancer Institute and Hospital , Chinese Academy of Medical Sciences, Beijing, China
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06781086
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
A Phase I Clinical Trial of JH013 Injection
Phase 1
Not yet recruiting
- Conditions
- Healthy Subjects (HS)
- Interventions
- Drug: JH013 injectionDrug: Placebo
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06633055
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Phase 3
Not yet recruiting
- Conditions
- Refractory Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06343116
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found